[{"id":"2698d9cc-7b84-4f76-aa1a-1e9120402516","acronym":"MAVRiC","url":"https://clinicaltrials.gov/study/NCT07024706","created_at":"2025-06-21T13:19:49.221Z","updated_at":"2025-06-21T13:19:49.221Z","phase":"Phase 2","brief_title":"Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab","source_id_and_acronym":"NCT07024706 - MAVRiC","lead_sponsor":"AstraZeneca","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/30/2025","start_date":" 09/30/2025","primary_txt":" Primary completion: 11/30/2032","primary_completion_date":" 11/30/2032","study_txt":" Completion: 11/30/2032","study_completion_date":" 11/30/2032","last_update_posted":"2025-06-17"},{"id":"5d9596a1-d384-4d3e-99e8-4001de1a4302","acronym":"EVOLVE CLL/SLL","url":"https://clinicaltrials.gov/study/NCT04269902","created_at":"2021-01-18T20:44:42.322Z","updated_at":"2025-02-25T12:27:29.630Z","phase":"Phase 3","brief_title":"Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study","source_id_and_acronym":"NCT04269902 - EVOLVE CLL/SLL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 247","initiation":"Initiation: 03/02/2021","start_date":" 03/02/2021","primary_txt":" Primary completion: 10/01/2028","primary_completion_date":" 10/01/2028","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2025-02-24"},{"id":"7d526185-7f46-4c4c-8f3a-7efa8cb4410a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03516617","created_at":"2021-01-18T17:18:31.951Z","updated_at":"2025-02-25T12:26:55.184Z","phase":"Phase 2","brief_title":"Acalabrutinib with or Without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT03516617","lead_sponsor":"Mayo Clinic","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/10/2018","start_date":" 09/10/2018","primary_txt":" Primary completion: 03/15/2030","primary_completion_date":" 03/15/2030","study_txt":" Completion: 03/15/2031","study_completion_date":" 03/15/2031","last_update_posted":"2025-02-24"},{"id":"88783755-7459-4207-a7a6-0af081a9d60d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01496976","created_at":"2021-01-18T06:16:27.062Z","updated_at":"2025-02-25T13:48:06.671Z","phase":"Phase 2","brief_title":"Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL","source_id_and_acronym":"NCT01496976","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD20 • CD5","pipe":"","alterations":" ","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Arzerra (ofatumumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/30/2012","start_date":" 03/30/2012","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 03/25/2025","study_completion_date":" 03/25/2025","last_update_posted":"2025-02-21"},{"id":"e2ff7fb5-f1de-4b7f-9fd4-438675875b61","acronym":"","url":"https://clinicaltrials.gov/study/NCT02160015","created_at":"2021-01-18T10:03:19.018Z","updated_at":"2025-02-25T13:52:04.076Z","phase":"Phase 1","brief_title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","source_id_and_acronym":"NCT02160015","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD4 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD4 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Rituxan (rituximab) • lenalidomide • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 05/20/2014","start_date":" 05/20/2014","primary_txt":" Primary completion: 03/27/2017","primary_completion_date":" 03/27/2017","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2025-02-20"},{"id":"113cfda4-7d09-419b-a619-1fc822fa3cf6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03088878","created_at":"2021-01-18T15:13:07.925Z","updated_at":"2025-02-25T15:17:25.790Z","phase":"Phase 1/2","brief_title":"A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies","source_id_and_acronym":"NCT03088878","lead_sponsor":"Oncternal Therapeutics, Inc","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • zilovertamab (UC-961)"],"overall_status":"Completed","enrollment":" Enrollment 95","initiation":"Initiation: 01/03/2018","start_date":" 01/03/2018","primary_txt":" Primary completion: 09/25/2024","primary_completion_date":" 09/25/2024","study_txt":" Completion: 09/25/2024","study_completion_date":" 09/25/2024","last_update_posted":"2025-02-12"},{"id":"814f07a4-6ae3-424e-b8de-ef7b7143e4c7","acronym":"BELLWAVE-010","url":"https://clinicaltrials.gov/study/NCT05947851","created_at":"2023-07-17T14:08:45.600Z","updated_at":"2025-02-25T15:28:11.395Z","phase":"Phase 3","brief_title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","source_id_and_acronym":"NCT05947851 - BELLWAVE-010","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" TP53 • BTK • IGH","pipe":" | ","alterations":" TP53 mutation • IGH mutation","tags":["TP53 • BTK • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • IGH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • nemtabrutinib (MK-1026)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 06/27/2033","primary_completion_date":" 06/27/2033","study_txt":" Completion: 06/27/2033","study_completion_date":" 06/27/2033","last_update_posted":"2025-02-11"},{"id":"6d960e71-ed2a-4ebb-b9a5-92e7b593b1dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02629809","created_at":"2021-01-18T12:47:12.967Z","updated_at":"2025-02-25T15:25:24.207Z","phase":"Phase 2","brief_title":"Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT02629809","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • Gazyva (obinutuzumab) • cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/18/2016","start_date":" 03/18/2016","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2025-02-10"},{"id":"7aa05467-0129-42a5-a27e-e92acdec8860","acronym":"","url":"https://clinicaltrials.gov/study/NCT03701282","created_at":"2021-01-18T18:08:23.751Z","updated_at":"2025-02-25T15:43:14.904Z","phase":"Phase 3","brief_title":"Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03701282","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 05/07/2028","primary_completion_date":" 05/07/2028","study_txt":" Completion: 05/07/2028","study_completion_date":" 05/07/2028","last_update_posted":"2025-02-10"},{"id":"cf9e772d-2d61-448f-ba42-778f71f83dc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04169737","created_at":"2021-01-18T20:20:34.948Z","updated_at":"2025-02-25T15:26:14.343Z","phase":"Phase 2","brief_title":"Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","source_id_and_acronym":"NCT04169737","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Gazyva (obinutuzumab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 07/09/2026","primary_completion_date":" 07/09/2026","study_txt":" Completion: 07/09/2026","study_completion_date":" 07/09/2026","last_update_posted":"2025-02-10"},{"id":"ebb921a0-be62-4f58-b2bf-73010372d9d7","acronym":"A041702","url":"https://clinicaltrials.gov/study/NCT03737981","created_at":"2021-01-18T18:18:31.892Z","updated_at":"2025-02-25T15:34:13.549Z","phase":"Phase 3","brief_title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT03737981 - A041702","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 454","initiation":"Initiation: 01/31/2019","start_date":" 01/31/2019","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-10"},{"id":"34fc9663-32b3-44fd-bd73-c0d19f0a1fc3","acronym":"SAVE","url":"https://clinicaltrials.gov/study/NCT04843904","created_at":"2021-04-14T11:52:49.393Z","updated_at":"2025-02-25T16:45:23.933Z","phase":"Phase 1","brief_title":"Safe Accelerated Venetoclax Escalation in CLL","source_id_and_acronym":"NCT04843904 - SAVE","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Rituxan (rituximab) • Gazyva (obinutuzumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 06/02/2025","primary_completion_date":" 06/02/2025","study_txt":" Completion: 06/02/2030","study_completion_date":" 06/02/2030","last_update_posted":"2025-02-05"},{"id":"7f3a4417-d9e1-41f2-85e6-183300a2b151","acronym":"NCI-2017-01311","url":"https://clinicaltrials.gov/study/NCT03246906","created_at":"2021-01-18T16:02:34.370Z","updated_at":"2025-02-25T16:44:11.978Z","phase":"Phase 2","brief_title":"Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation","source_id_and_acronym":"NCT03246906 - NCI-2017-01311","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • cyclosporin A microemulsion • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/11/2017","start_date":" 09/11/2017","primary_txt":" Primary completion: 05/03/2025","primary_completion_date":" 05/03/2025","study_txt":" Completion: 05/03/2025","study_completion_date":" 05/03/2025","last_update_posted":"2025-02-05"},{"id":"0d9ce0fd-f1c5-49a0-8195-840b50eca958","acronym":"MT2015-29","url":"https://clinicaltrials.gov/study/NCT03314974","created_at":"2021-01-18T16:22:16.872Z","updated_at":"2025-02-25T16:52:01.168Z","phase":"Phase 2","brief_title":"Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders","source_id_and_acronym":"NCT03314974 - MT2015-29","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPM1 • KMT2A • IKZF1 • CEBPA","pipe":" | ","alterations":" NPM1 mutation • MLL rearrangement","tags":["NPM1 • KMT2A • IKZF1 • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2026","study_completion_date":" 06/10/2026","last_update_posted":"2025-02-04"},{"id":"a3defc3d-df49-43a3-8fb7-35111287e449","acronym":"NCI-2016-00797","url":"https://clinicaltrials.gov/study/NCT02756897","created_at":"2021-01-18T13:30:56.475Z","updated_at":"2025-02-25T17:23:07.242Z","phase":"Phase 2","brief_title":"Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia","source_id_and_acronym":"NCT02756897 - NCI-2016-00797","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • IGH","pipe":" | ","alterations":" TP53 mutation • Chr del(11q)","tags":["TP53 • IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Imbruvica (ibrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 234","initiation":"Initiation: 07/07/2016","start_date":" 07/07/2016","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-01-31"},{"id":"b4bf5e45-657b-45ed-b417-1f3548a2653e","acronym":"15-H-0016","url":"https://clinicaltrials.gov/study/NCT02337829","created_at":"2021-01-18T11:06:16.803Z","updated_at":"2025-02-25T17:29:13.836Z","phase":"Phase 2","brief_title":"Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL","source_id_and_acronym":"NCT02337829 - 15-H-0016","lead_sponsor":"Acerta Pharma BV","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/12/2015","start_date":" 01/12/2015","primary_txt":" Primary completion: 06/26/2020","primary_completion_date":" 06/26/2020","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-30"},{"id":"22cade4d-b629-4125-adda-f63eccc24007","acronym":"","url":"https://clinicaltrials.gov/study/NCT04781855","created_at":"2021-03-04T12:52:18.890Z","updated_at":"2025-02-25T17:37:01.663Z","phase":"Phase 1","brief_title":"Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation","source_id_and_acronym":"NCT04781855","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Imbruvica (ibrutinib) • CS1002 (ipilimumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-01-29"},{"id":"b3cbc60c-b805-4974-b2a9-560e9eb38edd","acronym":"NCI-2018-00315","url":"https://clinicaltrials.gov/study/NCT03479268","created_at":"2021-01-18T17:08:37.744Z","updated_at":"2025-02-25T17:35:59.375Z","phase":"Phase 1","brief_title":"Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT03479268 - NCI-2018-00315","lead_sponsor":"City of Hope Medical Center","biomarkers":" CCND1 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CCND1 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 03/22/2018","start_date":" 03/22/2018","primary_txt":" Primary completion: 06/22/2025","primary_completion_date":" 06/22/2025","study_txt":" Completion: 06/22/2025","study_completion_date":" 06/22/2025","last_update_posted":"2025-01-29"},{"id":"1631cb9a-3bed-4607-9043-c30f2e5af7df","acronym":"ZE50-0134-0002","url":"https://clinicaltrials.gov/study/NCT06708897","created_at":"2025-02-26T11:42:54.327Z","updated_at":"2025-02-26T11:42:54.327Z","phase":"Phase 1","brief_title":"A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas","source_id_and_acronym":"NCT06708897 - ZE50-0134-0002","lead_sponsor":"Eilean Therapeutics","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-11-27"},{"id":"447ed126-6f5f-4987-b043-27e335f9b442","acronym":"C1763102","url":"https://clinicaltrials.gov/study/NCT05602363","created_at":"2024-01-29T15:19:20.293Z","updated_at":"2025-02-25T14:09:14.782Z","phase":"Phase 1","brief_title":"AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05602363 - C1763102","lead_sponsor":"Carna Biosciences, Inc.","biomarkers":" PLCG2","pipe":" | ","alterations":" PLCG2 mutation","tags":["PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PLCG2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docirbrutinib (AS-1763)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2027","primary_completion_date":" 09/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-11-01"},{"id":"27c5f328-4ffe-4a0e-bcaf-459f3ab39c44","acronym":"FOLLOW","url":"https://clinicaltrials.gov/study/NCT05590702","created_at":"2022-10-21T13:56:03.653Z","updated_at":"2025-02-25T15:00:41.794Z","phase":"","brief_title":"French Observational Study of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in Real-World Settings","source_id_and_acronym":"NCT05590702 - FOLLOW","lead_sponsor":"French Innovative Leukemia Organisation","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 11/11/2022","start_date":" 11/11/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2032","study_completion_date":" 12/01/2032","last_update_posted":"2024-10-29"},{"id":"ed362182-add1-434a-b6df-44f932cad804","acronym":"","url":"https://clinicaltrials.gov/study/NCT02135133","created_at":"2021-01-18T09:54:33.334Z","updated_at":"2025-02-25T13:11:11.926Z","phase":"Phase 2","brief_title":"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL","source_id_and_acronym":"NCT02135133","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD19 • CCND1 • CD5 • FCER2","pipe":" | ","alterations":" Chr t(11;14)","tags":["CD19 • CCND1 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zydelig (idelalisib) • Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 27","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 10/06/2020","primary_completion_date":" 10/06/2020","study_txt":" Completion: 10/06/2020","study_completion_date":" 10/06/2020","last_update_posted":"2024-10-16"},{"id":"ade707b7-5e5b-4f00-a824-2c91c94d8afe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04578600","created_at":"2021-01-18T21:51:14.278Z","updated_at":"2025-02-25T14:29:38.782Z","phase":"Phase 1","brief_title":"CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma","source_id_and_acronym":"NCT04578600","lead_sponsor":"Joseph Tuscano","biomarkers":" CD20 • CD4","pipe":"","alterations":" ","tags":["CD20 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Gazyva (obinutuzumab) • Onureg (azacitidine oral)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 10/23/2020","start_date":" 10/23/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-09-19"},{"id":"da7c1c4e-12fb-4361-97e1-5845011e3482","acronym":"","url":"https://clinicaltrials.gov/study/NCT01243190","created_at":"2021-01-18T05:00:24.541Z","updated_at":"2025-02-25T13:16:23.958Z","phase":"Phase 2","brief_title":"Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","source_id_and_acronym":"NCT01243190","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IGH • CD38","pipe":" | ","alterations":" CD38 positive","tags":["IGH • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Arzerra (ofatumumab)"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 03/28/2023","primary_completion_date":" 03/28/2023","study_txt":" Completion: 03/28/2023","study_completion_date":" 03/28/2023","last_update_posted":"2024-09-19"}]